M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 51 of 54
Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery
NCT00501319
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
NCT00059618
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
NCT00050531
Randomized Double Cord Blood Transplant Study
NCT00067002
Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00423436
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
NCT00059631
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
NCT00508703
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
NCT00509860
Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer
NCT00059605
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
NCT01099202
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
NCT00353015
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
NCT00505921
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients
NCT00506311
Exercise Program for Adolescents and Young Adults With Cancer
NCT00502749
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
NCT00500578
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
NCT00499889
Tissue Repair in Stem Cell Transplant Recipients
NCT00501228
Pain Quantification and Pain Management in Interventional Radiology (IR)
NCT00500942
Simple Versus Radical Hysterectomy for Stage I Cervical Cancer
NCT00506376
In Vivo Confocal Imaging of Oral Mucosa
NCT00502125
Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma
NCT00502411
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
NCT00501644
3-Dimensional Form and Soft Tissue Biomechanics of the Breast
NCT00502814
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
NCT00050986
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01082939
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
NCT00047489
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
NCT00685568
Melanoma Risk-Reduction Among Patients and Family Members
NCT00510302
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
NCT00047502
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT00429494
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
NCT01207635
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
NCT00671658
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
NCT00050167
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
NCT00502502
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
NCT00048737
Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia
NCT00102661
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
NCT00040105
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
NCT00071396
Sexual Functioning in Cervical Cancer Survivors
NCT00522223
Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis
NCT00059345
Lymphoscintigraphy in Patients With Vaginal Cancer
NCT00528034
Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia
NCT00513123
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
NCT00047710
Biobehavioral Effects of Emotional Expression in Cancer
NCT00505310
Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate
NCT02361125
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
NCT00043823
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
NCT00669877
Herceptin and GM-CSF for Metastatic Breast Cancer
NCT00429104
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
NCT00046865
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
NCT00043810
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.